Keyphrases
Methicillin-resistant Staphylococcus Aureus
64%
Influenza Virus
61%
COVID-19
61%
Pseudomonas Aeruginosa (P. aeruginosa)
58%
Pneumonia
52%
Japan
52%
Lung
43%
Streptococcus Pneumoniae
42%
Herpes Simplex Virus 2 (HSV-2)
42%
Azithromycin
40%
Murine Model
39%
Airway Epithelial Cells
38%
β-lactamase
35%
In Vivo Efficacy
34%
Quantitative PCR
34%
VacA
33%
Helicobacter Pylori (H. pylori)
33%
Mucin 5AC (MUC5AC)
33%
Mouse Model
33%
Gene Products
32%
Risk Factors
31%
Meropenem
30%
Vancomycin
29%
Haemophilus Influenzae
27%
Influenza-like Illness
27%
Infectious Diseases
25%
Nagasaki
25%
Protease
25%
Klebsiella Pneumoniae (K. pneumoniae)
23%
Metallo-β-lactamase
23%
Indonesia
22%
Chronic Pulmonary Aspergillosis
22%
Clarithromycin
22%
Macrolides
21%
S. Pneumoniae
21%
Infected Cells
21%
Hematogenous
21%
Antibacterial Susceptibility
21%
Clinical Characteristics
20%
Trypsin
20%
Antibiotics
20%
University Hospital
20%
Community-acquired Pneumonia
20%
Post-infection
20%
Clinical Microbiology
20%
Ventilator-associated Pneumonia
19%
Chemotherapy
19%
Pulmonary Infection
19%
Bacterial Respiratory Pathogens
18%
Japanese Society
18%
Nationwide Surveillance
18%
Minimum Inhibitory Concentration
18%
Molecular Diagnostics
18%
Airway
18%
Acute Respiratory Tract Infection
17%
Legionella Pneumophila
17%
Carbapenems
17%
Respiratory Infection
17%
Vacuolating Cytotoxin
16%
Neutralizing Antibodies
16%
Virus
16%
Herpes Simplex Virus Type 1 (HSV-1)
16%
Antimicrobial Susceptibility
15%
Viral Load
15%
Extended-spectrum-lactamase
14%
Virus Infection
14%
Clostridioides Difficile
14%
Fluoroquinolone Resistance
14%
Fluoroquinolones
14%
Ampicillin Resistance
14%
Patients with COVID-19
14%
Sendai Virus
14%
Infectivity
14%
Levofloxacin
13%
Human Influenza
13%
Clinical Features
13%
Cefepime
13%
Tertiary Hospital
13%
Sitafloxacin
13%
Resistant Strains
12%
Nucleic Acid Testing
12%
Healthcare-associated Pneumonia
12%
Enterobacteriaceae
12%
Adult T-cell Leukemia
12%
Overexpression
12%
Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)
12%
Performance Evaluation
12%
Survival Rate
12%
Fusobacterium nucleatum (F. nucleatum)
12%
Quinolones
11%
CA-MRSA
11%
Bronchoalveolar Lavage Fluid
11%
Quinolone Resistance-determining Region
11%
DNA Synthesis
11%
Combination Therapy
11%
Bacteremia
11%
Immunomodulatory Effect
11%
Carbapenem Resistance
11%
Infection Model
10%
Older Men
10%
Immunology and Microbiology
Methicillin-Resistant Staphylococcus Aureus
63%
Influenza Virus
49%
Infectious Agent
46%
Pneumococcus
42%
Herpes Simplex Virus 2
42%
Influenzavirus A
41%
Minimum Inhibitory Concentration
36%
Viral Disease
34%
Helicobacter Pylori
33%
Gene Product
33%
COVID-19
32%
Severe Acute Respiratory Syndrome Coronavirus 2
30%
Glycoprotein
28%
Influenza
27%
Pseudomonas aeruginosa
25%
MUC5AC
25%
DNA Virus
24%
Staphylococcus Aureus
23%
Immunology
22%
Neutralizing Antibody
22%
Infectious Disease
22%
Haemophilus influenzae
21%
Streptococcus Pneumonia
21%
DNA Synthesis
20%
Mouse Model
19%
Clinical Microbiology
18%
Antibiotic Sensitivity
18%
Mitochondrion
16%
Klebsiella pneumoniae
16%
Viral Load
16%
Immunofluorescence
16%
Wild Type
15%
Penicillin
15%
Plasmid
15%
Enterobacteriaceae
14%
Survival Rate
14%
Human Alphaherpesvirus 1
14%
Escherichia coli
14%
Bronchoalveolar Lavage Fluid
14%
Viral Replication
14%
Abscess
13%
Legionella pneumophila
12%
Epstein Barr Virus
12%
Virion
12%
Amino Terminal Sequence
12%
Cytokine
12%
Upper Respiratory Tract
12%
Viral Entry
11%
Capsid
11%
Colony Forming Unit S
11%
Virogenesis
11%
Pharmacokinetics
11%
Antiserum
11%
interferon
11%
Pathogenicity
11%
Antibody Response
11%
Sendai Virus
10%
Omicron Coronavirus Variant
10%
Aspergillus
10%
Matrix-Assisted Laser Desorption-Ionization
10%
Cell Death
10%
Neutralization
10%
Precursor
10%
Human T-Lymphotropic Virus 1
10%
Viral Envelope
9%
Virus Infectivity
9%
DNA Polymerase
9%
Fusobacterium nucleatum
9%
Mitochondrial Membrane Potential
9%
Antimicrobial Resistance
9%
Hemagglutinin
8%
Gene Expression
8%
Aspergillus fumigatus
8%
Genetic Transfection
8%
T Cell
8%
Multiplex Polymerase Chain Reaction
8%
Real Time Polymerase Chain Reaction
8%
Pyrosequencing
8%
Cytomegalovirus
8%
Acinetobacter Baumannii
8%
Prevotella intermedia
8%
Aeromonas
8%
Fusobacterium necrophorum
8%
Western Blot
8%
Drug Megadose
8%
Polyclonal Antiserum
8%
Leporidae
8%
Cell Lysate
8%
Sputum
8%
Blood Plasma
8%
Morphology
7%
Supernatant
7%
Polymerase Chain Reaction
7%
Interleukin 6
7%
Mucin
7%
Microflora
7%
Pulmonary Inflammation
7%
Quantitative Reverse Transcription Polymerase Chain Reaction
7%
Molecular Weight
6%
Herpes Simplex Virus
6%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Methicillin-Resistant Staphylococcus Aureus
55%
Pseudomonas aeruginosa
54%
Penicillinase
42%
SARS Coronavirus
39%
Azithromycin
32%
Mucin 5AC
31%
Macrolide
29%
Respiratory Tract Infection
28%
Infectious Agent
26%
Antiinfective Agent
25%
Disease
25%
Helicobacter Pylori
25%
Quinolone Derivative
24%
Mouse Model
24%
Proteinase
23%
Vancomycin
23%
Virus Infection
20%
Streptococcus
20%
Pharmacokinetics
20%
Methicillin Resistant Staphylococcus Aureus Infection
20%
Vacuolating Toxin
18%
Clarithromycin
18%
Influenza Virus
17%
Haemophilus influenzae
17%
Meropenem
17%
Ventilator Associated Pneumonia
15%
Lung Infection
14%
Antibiotics
14%
Influenzavirus A
14%
Lung Aspergillosis
14%
Coronavirinae
14%
Bloodstream Infection
14%
Legionella pneumophila
13%
Sitafloxacin
13%
Mucin
12%
Severe Fever with Thrombocytopenia Syndrome
12%
Community Acquired Pneumonia
12%
Levofloxacin
11%
Neutralizing Antibody
11%
Messenger RNA
11%
Quinolone
11%
Staphylococcus Aureus
10%
Ampicillin
10%
Amphotericin B
10%
Carbapenem Resistance
10%
Cytokine
10%
Linezolid
10%
Garenoxacin
10%
Aspergillus
10%
Tumor Necrosis Factor
9%
Respiratory Failure
9%
Penicillin Derivative
9%
Glycoprotein
9%
Fusobacterium nucleatum
9%
Virus Infectivity
9%
Health Care Associated Pneumonia
9%
Biapenem
9%
Streptococcus Pneumonia
9%
Aspergillus fumigatus
9%
Chemotherapy
8%
Carbapenem
8%
Minimum Inhibitory Concentration
8%
Amino Acid
8%
Pazufloxacin
8%
Nontypeable Haemophilus Influenzae
8%
Habekacin
8%
Tedizolid
8%
T Cell Leukemia
8%
Inosine Phosphate
8%
Peptoclostridium difficile
8%
Tobramycin
8%
Herpes Simplex Virus 2
8%
Clinical Feature
8%
Interferon Type I
8%
Prevotella intermedia
8%
Acinetobacter Baumannii
8%
Antibiotic Resistance
8%
Aeromonas
8%
Itraconazole
8%
Carbapenem Derivative
8%
Pulmonary Surfactant
7%
Ciprofloxacin
7%
Aminoglycoside
7%
Fatality
7%
Interleukin 6
7%
Favipiravir
7%
Combination Therapy
7%
Survival Rate
7%
Adenosine Triphosphate
7%
Inflammation
6%
Klebsiella pneumoniae
6%
Panton-Valentine Leukocidin
6%
Antibiotic Therapy
6%
Metronidazole
6%
Moxifloxacin
6%
Randomized Controlled Trial
6%
Cytochrome C
6%
Triazole
6%
Molecular Epidemiology
6%